|

[18F]-APN-1607 Clinical Trials

2 actively recruiting trials

▲ +1 trial since August 2026

Pipeline

Phase 3: 2

Top Sponsors

  • JYAMS PET Research & Development Limited2

Indications

  • Alzheimer's Disease2
  • Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia1

Other2 trials

Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.
Phase 3
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.